Albuminuria: A Target for Treatment of Type 2 Diabetic Nephropathy

Seminars in Nephrology

Volumn 27, Issue 2, 2007, Pages 172-181

  de Zeeuw, Dick ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

albuminuria; cardiovascular risk; Diabetes; nephropathy; renin angiotensin system; treatment

Indexed keywords

ALBUMIN; ALDOSTERONE ANTAGONIST; ENDOTHELIN RECEPTOR ANTAGONIST; GLUCOSE; GLYCOSAMINOGLYCAN; LIPID; RENIN INHIBITOR; STATIN; SULODEXIDE; VITAMIN D;

ALBUMINURIA; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETIC NEPHROPATHY; HUMAN; KIDNEY FUNCTION; LIFESTYLE; LIPID BLOOD LEVEL; MEASUREMENT; MICROALBUMINURIA; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTOR VARIABLE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR;

ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; HUMANS; PROGNOSIS; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS;

EID: 34047265646     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2007.01.002     Document Type: Article

References (53)

1. Haffner S.M., Lehto S., Ronnemaa T., Pyorala K., and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339 (1998) 229-234
2. Keane W.F., Brenner B.M., de Zeeuw D., Grunfeld J.P., Lash J., Lyle P.A., et al., RENAAL Study Investigators. A risk score for predicting end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Clin J Am Soc Nephrol 1 (2006) 761-767
3. Levey A.S., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 67 (2005) 2089-2100
4. Hillege H.L., Fidler V., Diercks G.F., van Gilst W.H., de Zeeuw D., van Veldhuisen D.J., et al., Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 106 (2002) 1777-1782
5. Klausen K., Borch-Johnsen K., Feldt-Rasmussen B., Jensen G., Clausen P., Scharling H., et al. Very low levels of microalbuminuria are associated with increased risk of coronary heart disease and death independently of renal function, hypertension, and diabetes. Circulation 110 (2004) 32-35
6. Verhave J.C., Gansevoort R.T., Hillege H.L., Bakker S.J., De Zeeuw D., de Jong P.E., and PREVEND Study Group. An elevated urinary albumin excretion predicts de novo development of renal function impairment in the general population. Kidney Int Suppl 92 (2004) S18-S21
7. Ruggenenti P., and Remuzzi G. Time to abandon microalbuminuria?. Kidney Int 70 (2006) 1214-1222
8. Zandi-Nejad K., Eddy A.A., Glassock R.J., and Brenner B.M. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl 92 (2004) S76-S89
9. Brinkman J.W., Bakker S.J., Gansevoort R.T., Hillege H.L., Kema I.P., Gans R.O., et al. Which method for quantifying urinary albumin excretion gives what outcome?. A comparison of immunonephelometry with HPLC. Kidney Int Suppl 92 (2004) S69-S75
10. Polkinghorne K.R., Su Q., Chadban S.J., Shaw J.E., Zimmet P.Z., and Atkins R.C. Population prevalence of albuminuria in the Australian Diabetes, Obesity, and Lifestyle (AusDiab) study: immunonephelometry compared with high-performance liquid chromatography. Am J Kidney Dis 47 (2006) 604-613
11. Florvall G., Basu S., Helmersson J., and Larsson A. Hemocue urine albumin point-of-care test shows strong agreement with the results obtained with a large nephelometer. Diabetes Care 29 (2006) 422-423
12. Mogensen C.E. Microalbuminuria as a predictor of clinical diabetic nephropathy. Kidney Int 31 (1987) 673-689
13. Berrut G., Bouhanick B., Fabbri P., Guilloteau G., Bled F., Le Jeune J.J., et al. Microalbuminuria as a predictor of a drop in glomerular filtration rate in subjects with non-insulin-dependent diabetes mellitus and hypertension. Clin Nephrol 48 (1997) 92-97
14. Nosadini R., and Tonolo G. Blood glucose and lipid control as risk factors in the progression of renal damage in type 2 diabetes. J Nephrol 16 Suppl 7 (2003) S42-S47
15. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310 (1984) 356-360
16. Nelson R.G., Knowler W.C., Pettitt D.J., Saad M.F., Charles M.A., and Bennett P.H. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 151 (1991) 1761-1765
17. Ruggenenti P., Fassi A., Ilieva A.P., Bruno S., Iliev I.P., Brusegan V., et al., Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351 (2004) 1941-1951
18. Remuzzi G., and Bertani T. Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?. Kidney Int 38 (1990) 384-394
19. Abbate M., Zoja C., and Remuzzi G. How does proteinuria cause progressive renal damage?. J Am Soc Nephrol 17 (2006) 2974-2984
20. Ruggenenti P., Perna A., Mosconi L., Pisoni R., Remuzzi G., and "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN). Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney Int 53 (1998) 1209-1216
21. Brenner B.M., Cooper M.E., de Zeeuw D., Keane W.F., Mitch W.E., Parving H.H., et al., RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345 (2001) 861-869
22. Lewis E.J., Hunsicker L.G., Clarke W.R., Berl T., Pohl M.A., Lewis J.B., et al., Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345 (2001) 851-860
23. Keane W.F., Brenner B.M., de Zeeuw D., Grunfeld J.P., McGill J., Mitch W.E., et al., RENAAL Study Investigators. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 63 (2003) 1499-1507
24. Atkins R.C., Briganti E.M., Lewis J.B., Hunsicker L.G., Braden G., Champion de Crespigny P.J., et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy. Am J Kidney Dis 45 (2005) 281-287
25. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G., and The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med 342 (2000) 145-153
26. Mogensen C.E. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310 (1984) 356-360
27. Marshall S.M. Blood pressure control, microalbuminuria and cardiovascular risk in type 2 diabetes mellitus. Diabet Med 16 (1999) 358-372
28. Yuyun M.F., Dinneen S.F., Edwards O.M., Wood E., and Wareham N.J. Absolute level and rate of change of albuminuria over 1 year independently predict mortality and cardiovascular events in patients with diabetic nephropathy. Diabet Med 20 (2003) 277-282
29. Sukhija R., Aronow W.S., Kakar P., Garza L., Sachdeva R., Sinha A., et al. Relation of microalbuminuria and coronary artery disease in patients with and without diabetes mellitus. Am J Cardiol 98 (2006) 279-281
30. Mykkanen L., Zaccaro D.J., O'Leary D.H., Howard G., Robbins D.C., and Haffner S.M. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. The Insulin Resistance Atherosclerosis Study (IRAS). Stroke 28 (1997) 1710-1716
31. Keech A.C., Grieve S.M., Patel A., Griffiths K., Skilton M., Watts G.F., et al. Urinary albumin levels in the normal range determine arterial wall thickness in adults with type 2 diabetes: a FIELD substudy. Diabet Med 22 (2005) 1558-1565
32. Dinneen S.F., and Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch Intern Med 157 (1997) 1413-1418
33. Kannel W.B., Stampfer M.J., Castelli W.P., and Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 108 (1984) 1347-1352
34. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy. Circulation 110 (2004) 921-927
35. Anavekar N.S., Gans D.J., Berl T., Rohde R.D., Cooper W., Bhaumik A., et al. Predictors of cardiovascular events in patients with type 2 diabetic nephropathy and hypertension: a case for albuminuria. Kidney Int Suppl 92 (2004) S50-S55
36. Vogt L., Navis G., and de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics?. J Am Soc Nephrol 13 Suppl 3 (2002) S202-S207
37. Rossing P., Hommel E., Smidt U.M., and Parving H.H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 37 (1994) 511-516
38. Apperloo A.J., de Zeeuw D., and de Jong P.E. Short-term antiproteinuric response to antihypertensive treatment predicts long-term GFR decline in patients with non-diabetic renal disease. Kidney Int Suppl 45 (1994) S174-S178
39. Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., and The Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329 (1993) 1456-1462
40. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349 (1997) 1857-1863
41. de Zeeuw D., Remuzzi G., Parving H.H., Keane W.F., Zhang Z., Shahinfar S., et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 65 (2004) 2309-2320
42. Parving H.H., Lehnert H., Brochner-Mortensen J., Gomis R., Andersen S., and Arner P. Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345 (2001) 870-878
43. Andersen S., Brochner-Mortensen J., and Parving H.H. Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria Study Group. Kidney function during and after withdrawal of long-term irbesartan treatment in patients with type 2 diabetes and microalbuminuria. Diabetes Care 26 (2003) 3296-3302
44. Eijkelkamp WBA, Zhang Z, Remuzzi G, Parving H-H, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post-hoc analysis from the RENAAL trial. JASN. In press.
45. Lindholm L.H., Ibsen H., Dahlof B., Devereux R.B., Beevers G., de Faire U., et al., LIFE Study Group. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 1004-1010
46. Ibsen H., Olsen M.H., Wachtell K., Borch-Johnsen K., Lindholm L.H., Mogensen C.E., et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension 45 (2005) 198-202
47. Asselbergs F.W., Diercks G.F., Hillege H.L., van Boven A.J., Janssen W.M., Voors A.A., et al., Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators. Effects of fosinopril and pravastatin on cardiovascular events in subjects with microalbuminuria. Circulation 110 (2004) 2809-2816
48. Buter H., Hemmelder M.H., Navis G., de Jong P.E., and de Zeeuw D. The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide. Nephrol Dial Transplant 13 (1998) 1682-1685
49. Schmieder R.E., Klingbeil A.U., Fleischmann E.H., Veelken R., and Delles C. Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16 (2005) 3038-3045
50. Rossing K., Schjoedt K.J., Jensen B.R., Boomsma F., and Parving H.H. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68 (2005) 1190-1198
51. Gambaro G., Kinalska I., Oksa A., Pont'uch P., Hertlova M., Olsovsky J., et al. Oral sulodexide reduces albuminuria in microalbuminuric and macroalbuminuric type 1 and type 2 diabetic patients: the Di.N.A.S. Randomized trial. J Am Soc Nephrol 13 (2002) 1615-1625
52. Agarwal R., Acharya M., Tian J., Hippensteel R.L., Melnick J.Z., Qiu P., et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 68 (2005) 2823-2828
53. Palmer A.J., Annemans L., Roze S., Lamotte M., Lapuerta P., Chen R., et al. Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27 (2004) 1897-1903